Biology of malignant hyperthermia: A disease of the calcium channels of the skeletal muscle;Biologie de l'hyperthermie maligne: Une maladie des canaux calciques du muscle squelettique

Annales de Biologie Clinique

Volumn 58, Issue 2, 2000, Pages 147-156

  Monnier, N ^a   Lunardi, J ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Calcium channels; Malignant hyperthermia; Skeletal muscle

Indexed keywords

ADENOSINE TRIPHOSPHATE; CAFFEINE; CALCIUM ION; CALMODULIN; CREATINE KINASE; DANTROLENE; GLUCOSE 6 PHOSPHATE ISOMERASE; HALOTHANE; INHALATION ANESTHETIC AGENT; LACTIC ACID; MYOGLOBIN; RYANODINE RECEPTOR;

ANIMAL; CALCIUM CHANNEL; CALCIUM HOMEOSTASIS; GENE MUTATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; HYPERMETABOLISM; HYPERTHERMIA; MALIGNANT HYPERTHERMIA; METABOLISM; MUSCLE CONTRACTION; MUSCLE RIGIDITY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SARCOPLASMIC RETICULUM; SKELETAL MUSCLE;

ANIMALS; CALCIUM CHANNELS; HUMANS; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTION; MUSCLE, SKELETAL; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

ANIMALIA; SUIDAE; SUS SCROFA;

EID: 0034069060     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Denborough MA, Lovell RRH. Anesthetic deaths in a family. Lancet 1960 ; ii : 45.
2. Ebashi S, Endo M, Ohtsuki I. Control of muscle contraction. Quart Rev Biophys 1969 ; 2 : 351-84.
3. Tanabe T, Beam KG, Powell JA, Nulma S. Restoration of excitation-contraction coupling and slow calcium currents in dysgenic mice by dihydropyridine receptor complementary DNA. Nature 1988 ; 336 : 134-9.
4. 2+ release channels and their regulation by endogenous effectors. Annu Rev Physiol 1994 ; 56 : 485-508.
5. Coronado R, Morissette J, Sukhareva M, Vaughan DM. Structure and function of ryanodine receptors. Am J Physiol 1994 ; 266 : C1485-504.
6. Clapham DE. Calcium signaling. Cell 1995 ; 80 : 259-68.
7. Britt BA. Malignant hyperthermia. In : Schonbaum E, Lomax P. Thermoregulation : pathology, pharmacology and therapy. New York, Pergamon Press, 1991 : 179-292.
8. Denborough MA. Malignant hyperthermia. Lancet 1998 ; 352 : 1131-6.
9. Fujii J, Otsu K, Zorzato F, et al. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991 ; 253 : 448-51.
10. Ellis FR, Harriman DGF, Keaney MP, Kyei-Mensah K, Tyrrel JH. Halothane induce muscle contracture as a cause of hyperpyrexia. Br J Anaesth 1971 ; 43 : 721-4.
11. European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984 ; 56 : 1267-9.
12. Larach MG. Standardization of the caffeine halothane muscle contracture test. Anesth Analg 1989 ; 69 : 511-5.
13. Hermann-Frank A, Richter M, Lehmann-Horn F. 4-chloro-m-cresol : a specific tool to distinguish between malignant hyperthermia-susceptible and normal muscle. Biochem Pharmacol 1996 ; 52 : 149-55.
14. Hopkins PM, Ellis FR, Halsall PJ, Stewart AD. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia. Anesthes Analges 1997 ; 84 : 648-56.
15. 31P-magnetic resonance spectroscopy. Anesthesiolagy 1993 ; 78 : 848-55.
16. Mickelson JR, Gallant EM, Litterer LA, Johnson KM, Rempel WE, Louis CF. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J Biol Chem 1988 ; 263 : 9310-5.
17. McCarthy TV, Healy JMS. Heffron JJA, et al. Localization of the malignant hyperthermia locus to human chromosome 19q12-13.2. Nature 1990 ; 343 : 562-4.
18. MacLennan DH, Duff C, Zorzato F, et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990 ; 343 : 559-61.
19. Gillard EF, Otsu K, Fujii J, et al. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 1991 ; 11 : 751-5.
20. Deufel T, Golla A, Iles D, et al. Evidence for genetic heterogenity of malignant hyperthemia susceptibility. Am J Hum Genet 1992 ; 50 : 1151-61.
21. 2+ release channels. Am J Med 1998 ; 104 : 470-86.
22. Leeb T, Brenig B. Ryanodine receptors and their role in genetic diseases. Int J Mol Med 1998 ; 2 : 293-300.
23. 2+ release channel function and severe central core disease. Proc Natl Acad Sci USA 1999 ; 96 : 4164-9.
24. 2+ release channels. J Biol Chem 1998 ; 274 : 693-702.
25. Richter M, Schleithoff L, Deufel T, et al. Functional characterisation of a distinct ryanodine receptor mutation in human malignant hyperthermia susceptible muscle. J Biol Chem 1997 ; 272 : 5256-60.
26. Monnier N, Procaccio V, Stieglitz P, Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the α1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Human Genet 1997 ; 60: 1316-25.
27. Ptacek LJ, Tawil R, Griggs RC. et al. Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell 1994 ; 77 : 863-8.
28. Leong P, MacLennan DH. The cytoplasmic loops between domain II and III and domains III and IV in the skeletal muscle dihydropyridine receptor bind to a continuous site in the skeletal muscle ryanodine receptor. J Biol Chem 1998 ; 273 : 29958-64.